Recent Posts
- Genome Atlantic – The Future of Personalized Health & Human Performance
- NEWS RELEASE – Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference
- Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical
- NEWS RELEASE – BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital
- ENTREVESTOR – Biotech Segment Continues To Grow